Halaman 1 dari 48 hasil
FIELD OF THE INVENTION
The present invention relates to certain compositions of a 5-HT.sub.2A serotonin receptor modulator and methods for their preparation. The compositions disclosed herein are useful for increasing slow wave sleep, improving sleep consolidation, improving sleep maintenance and
FIELD OF THE INVENTION
The present invention relates to certain compositions of a 5-HT.sub.2A serotonin receptor modulator and methods for their preparation. The compositions disclosed herein are useful for increasing slow wave sleep, improving sleep consolidation, improving sleep maintenance and
FIELD OF THE INVENTION
The present invention relates to certain compositions of a 5-HT.sub.2A serotonin receptor modulator and methods for their preparation. The compositions disclosed herein are useful for increasing slow wave sleep, improving sleep consolidation, improving sleep maintenance and
FIELD OF THE INVENTION
The present invention relates to certain compositions of a 5-HT.sub.2A serotonin receptor modulator and methods for their preparation. The compositions disclosed herein are useful for increasing slow wave sleep, improving sleep consolidation, improving sleep maintenance and
FIELD OF THE INVENTION
The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT.sub.2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of
FIELD OF THE INVENTION
The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT.sub.2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of
BACKGROUND OF THE INVENTION
This invention relates to treatments for stroke.
Stroke is a leading cause of death in the United States. The most common type of stroke, focal central nervous system (CNS) ischemia, is characterized by an acute onset of neurological deficit and is primarily caused by the
BACKGROUND OF THE INVENTION
This invention relates to treatments for stroke.
Stroke is a leading cause of death in the United States. The most common type of stroke, focal central nervous system (CNS) ischemia, is characterized by an acute onset of neurological deficit and is primarily caused by the
The invention relates to the use of active compounds which act as serotonin agonists and have a binding strength of less than 10,000 nmol/l on binding to 5HT.sub.1A receptors for the preparation of medicaments for the treatment of cerebral apoplexy.
Cerebral apoplexy (stroke, cerebrovascular
The invention relates to the use of active compounds which act as serotonin agonists and have a binding strength of less than 10,000 nmol/l on binding to 5HT.sub.1A receptors for the preparation of medicaments for the treatment of cerebral apoplexy.
Cerebral apoplexy (stroke, cerebrovascular
EXAMPLES
Test model
1. Occlusion of the middle cerebral artery in the rat
Under anaesthesia (N.sub.2 O/halothane) a skin incision is made centrally between the eye and ear and, by blunt dissection of the underlying areas of muscle, an access to the skull is created in the region of the foramen
The invention relates to the use of active compounds which act as serotonin agonists and have a binding strength of less than 10,000 nmol/l on binding to 5HT.sub.1A receptors for the preparation of medicaments for the treatment of cerebral apoplexy.
Cerebral apoplexy (stroke, cerebrovascular
BACKGROUND OF THE INVENTION
The field of the present invention relates to the delivery of energy impulses (and/or fields) to bodily tissues for therapeutic purposes. The invention relates more specifically to devices and methods for treating conditions associated with stroke and/or transient
BACKGROUND OF THE INVENTION
Serotonin is a vasoconstrictor and neurotransmitter present in the brain, intestinal tissue and blood platelets. Regulation of the binding of serotonin can provide a method of treatment and prevention of a variety of illnesses including central nervous disorders,
FIELD OF THE INVENTION
The present invention relates to certain diaryl and arylheteroaryl urea derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT.sub.2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to